Brexanolone (IV allopregnanolone) and zuranolone (oral neurosteroid) are FDA-approved for postpartum depression with the rapid antidepressant mechanism described in Stage 19.3. The clinical use is defined but limited by access and cost realities. Brexanolone requires 60-hour continuous IV infusion in REMS-required monitored setting; zuranolone is 14-day oral course taken at home. The treatments produce rapid response in postpartum depression — often within days rather than the weeks required by standard antidepressants — but have specific candidate selection, monitoring, and integration requirements.
Brexanolone (Zulresso) practical considerations. Continuous IV infusion over 60 hours; REMS-required administration in healthcare setting with continuous monitoring; cost approximately $34,000 for the course. The treatment infrastructure requirement is substantial; access is concentrated in specialty postpartum centers. Side effects include sedation (significant — the REMS program addresses falls and over-sedation risk), loss of consciousness in some patients, and the practical challenges of separation from infant during 60-hour infusion. The clinical place is moderate-to-severe postpartum depression where the rapid response is clinically valuable and the access infrastructure exists.
Zuranolone (Zurzuvae) practical considerations. 14-day oral course (50mg daily) for postpartum depression. Outpatient administration; substantially better access than brexanolone. Cost varies by insurance but in $15,000-20,000 range without coverage; insurance covers in many cases for the FDA-approved indication. Side effects include sedation (typically less severe than brexanolone), warning about driving and operating equipment, and the lactation consideration. The clinical place is broader than brexanolone — outpatient postpartum depression where rapid response is clinically valuable.
Candidate selection. Postpartum depression (within 12 months of delivery for FDA indication; some clinical use beyond this window). Severity warranting rapid response — moderate to severe depression. Adequate support for sedation effects. For zuranolone, willingness to follow lactation precautions or alternative feeding during treatment. Coordination with obstetrics and pediatrics for breastfeeding decisions. The lactation consideration. Both agents pass into breast milk; the clinical recommendations vary. Many patients are advised to pump and discard during treatment with feeding return after; others continue breastfeeding with clinical monitoring. The decision is patient-specific with informed consent about the data limitations.
Integration with broader postpartum care. The neurosteroid treatment produces rapid symptom reduction but is not standalone postpartum care. Coordinate with obstetrics, pediatrics, lactation consultation, mental health follow-up, family support. The acute treatment effect creates window for ongoing care — continued psychiatric follow-up, psychotherapy, lifestyle interventions, family system engagement. The 14-day or 60-hour treatment is part of a longer care arc, not the complete intervention. The discipline is to recognize when neurosteroid treatment fits the clinical picture (postpartum depression with severity warranting rapid response), navigate the access and cost realities, integrate with broader postpartum care, and use the acute treatment window to consolidate durable recovery.